MedTrace Logo

A Study of SYH2069 Injection in Healthy Participants

NCT07736391 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2026-07-30

No results posted yet for this study

Summary

To evaluate the safety and tolerability of single and multiple doses of SYH2069 Injection in healthy participants.

Conditions

Interventions

DRUG

SYH2069 Injection

A subcutaneous injection in the abdomen of the corresponding dose of SYH2069 Injection according to the assigned dose cohort.

DRUG

Placebo

A subcutaneous injection in the abdomen of the corresponding dose of Placebo according to the assigned dose cohort.

Sponsors & Collaborators

  • CSPC Ouyi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-10
Primary Completion
2026-07-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07736391 on ClinicalTrials.gov